http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-109402252-A
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_7c273e10b5c6cf688f12411bf17de7a0 |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-118 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-158 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2333-47 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-6886 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-57426 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-574 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-6886 |
| filingDate | 2017-08-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_19e777fec6f642bbb992e62cab00f726 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b53b672f815ae9761c18ebbd47e1fbd9 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f807765f50a520752317abe0b4ebf25a |
| publicationDate | 2019-03-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-109402252-A |
| titleOfInvention | Acute myeloid leukemia risk assessment gene markers and their applications |
| abstract | The present invention relates to an acute myeloid leukemia (AML) risk assessment gene marker and its application. By integrating clinical experimental data and public data resources, the inventors used a variety of bioinformatics analysis methods to analyze the key genes of AML occurrence or disease progression in general, and identified CEBPe as a key gene for acute myeloid leukemia survival and relapse , so as to propose a diagnostic method and a diagnostic kit targeting CEBPe. The bioinformatics analysis idea and method and the related diagnostic kit of the present invention are particularly suitable for the analysis and prediction of the survival time and recurrence of AML clinical patients. In addition, CEBPe-targeted genetic diagnosis kits can also subdivide low- and medium-risk AML patients such as non-elderly AML patients and non-mutated samples of oncogenes, and guide whether to perform allogeneic bone marrow transplantation. |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-111154881-A http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-113373228-A http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-110129449-A http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-110331205-A |
| priorityDate | 2017-08-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 432.